Yonsei Med J.
2023 Feb;64(2):86-93. 10.3349/ymj.2022.0244.
Effectiveness of Adding Docetaxel to Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer in Korean Real-World Practice
- Affiliations
-
- 1Medical Oncology and Hematology, Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan, Korea
- 2Division of Hemato-Oncology, Keimyung University Dongsan Hospital, Daegu, Korea
- 3Division of Medical Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea
- 4Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
- 5Department of Internal Medicine, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Korea
- 6Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea
- KMID: 2538957
- DOI: http://doi.org/10.3349/ymj.2022.0244
Abstract
- Purpose
Evidence in favor of adding docetaxel in treatment of metastatic hormone-sensitive prostate cancer (mHSPC) has led to docetaxel in conjunction with androgen deprivation therapy (ADT) as standard therapy. The aim of this study was to examine the effectiveness of docetaxel with ADT for Korean patients with mHSPC in real-world practice.
Materials and Methods
A retrospective cohort study was performed at six Korean hospitals for patients with mHSPC treated with docetaxel plus ADT. Patients were treated every 3 weeks for up to six cycles with 75 mg/m 2 of docetaxel. The primary endpoint was time to castration resistant prostate cancer (CRPC).
Results
This study included 46 eligible patients from June 2016 to February 2021. Median age was 68.5 years (range, 52–84) and all patients present with de novo M1 with high-volume disease. The median prostate-specific antigen (PSA) level at ADT initiation was 205.4 (7.7–1933) ng/mL, and time from ADT to docetaxel was 2.4 months (0–5.3). All six planned cycles of docetaxel were delivered in 36 patients (78%), 7 patients (15%) discontinued treatment due to adverse events, and 3 patients (7%) discontinued due to progression. At the time of the analysis, CRPC had developed in 34 patients (74%), and the median time to CRPC was 18.0 (95% confidence interval, 14.1–21.9) months. PSA <0.2 ng/mL was achieved in 11 patients (24%) after 6 months of ADT and in 10 patients (22%) after 12 months. At last follow-up, 35 patients (76%) were alive; the median overall survival was not reached.
Conclusion
The effect of docetaxel combined with ADT for Korean patients with mHSPC is comparable with prior results in Western studies.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Chemotherapy With Androgen Deprivation for Hormone-Naïve Prostate Cancer
- Systemic Therapies for Metastatic Castration-Resistant Prostate Cancer: An Updated Review
- Current Concepts in Androgen Deprivation Therapy
- Quality of Life in Prostate Cancer Patient Undergoing Androgen Deprivation Therapy
- Use of docetaxel plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer in Korean patients: A retrospective study
